<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> represents less than 1% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001297'>strokes</z:hpo>, being an uncommon entity with a wide spectrum of clinical scenarios </plain></SENT>
<SENT sid="1" pm="."><plain>We present a 45-year-old Hispanic female with a history of long-term oral contraceptive use who was diagnosed with cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> due to a heterozygous carrier mutation in the prothrombin G20210A gene </plain></SENT>
<SENT sid="2" pm="."><plain>The patient was successfully managed with intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> with favorable clinical results without adverse effects </plain></SENT>
<SENT sid="3" pm="."><plain>The prevalence of inherited primary <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> increases with additional risk factors such as the use of oral contraceptives that can trigger or prothrombotic events in any vascular bed </plain></SENT>
<SENT sid="4" pm="."><plain>An increased prevalence in the prothrombin G20210 gene mutation has been demonstrated in the Mexican-Mestizo population </plain></SENT>
<SENT sid="5" pm="."><plain>Controversy exists regarding therapy of cerebral venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp>; according to experts, <z:chebi fb="5" ids="28304">heparin</z:chebi> remains the cornerstone of therapy with acceptable outcomes </plain></SENT>
<SENT sid="6" pm="."><plain>More clinical trials are required to evaluate long-term outcomes in this subgroup of patients </plain></SENT>
</text></document>